AN ANALYSIS OF BANNED FIXED-DOSE COMBINATIONS IN INDIA

  • SHRUTI PATEL Department of Pharmacology, B. J. Medical College, Ahmedabad, Gujarat, India.
  • SAMIDH SHAH Department of Pharmacology, B. J. Medical College, Ahmedabad, Gujarat, India.
  • CHETNA DESAI Department of Pharmacology, B. J. Medical College, Ahmedabad, Gujarat, India.

Abstract

Objective: The objective of the study was to analyze the nonsteroidal anti-inflammatory drugs (NSAIDs) and respiratory fixed-dose combinations (FDCs) recently banned in India.


Methods: This observational study was conducted at the Department of Pharmacology, B. J. Medical College, Ahmedabad, Gujarat. The data were collected from the report on the banned FDCs submitted by the drug technical advisory board subcommittee. Total 195 FDCs belonging to NSAIDs (33) and respiratory group (162) were assessed for class, number of active pharmacological ingredients, formulations, indications, and reasons for banning.


Results: The mean number of drugs in FDCs of NSAIDs was 2.6, while in respiratory FDCs, it was 3.6. The most common NSAID formulation was uncoated tablet (15, 30%) while it was syrup in respiratory (49, 30%). The most common reasons for banning these FDCs were safety concerns (153, 78.4%), followed by mismatched pharmacodynamics in respiratory FDCs and mismatched pharmacokinetics in NSAIDs FDCs. The NSAIDs FDCs were marketed for pain (70%) while respiratory FDCs were marketed for cough and cold (62%). Most common NSAIDs FDCs contained NSAID with NSAID (18%), while in respiratory FDCs combinations of a cough suppressant, expectorant, and soothing agents (10%) were present.


Conclusion: Evaluation of FDCs is essential to prevent the marketing of irrational FDCs.

Keywords: Nonsteroidal anti-inflammatory drugs, Respiratory, Banned fixed-dose combinations, Irrational fixed-dose combinations

References

1. Department-Related Parliamentary Standing Committee on Health and Family Welfare. New Delhi: 59th Report on the Functioning of the Central Drugs Standard Control Organisation (CDSCO); 2012.
2. System of Preliminary Scrutiny by CDSCO at the Time of Receipt of Application for Approval of Fixed Dose Combinations (FDCs); 2011. Available from: https://www.cdsco.gov.in. [Last accessed on 2019 Sep 15].
3. Gupta YK, Ramchandran SS. Fixed dose drug combinations: Issues and challenges in India. Indian J Pharmacol 2016;48:347-9.
4. McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock AM. Use of fixed dose combination (FDC) drugs in India: Central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or psychotropic drugs. PLoS Med 2015;12:e1001826.
5. Rayasam SP, Dudhgaonkar SS, Dakhale GN, Hire RC, Deshmukh PS,Gaikwad NN. The irrational fi xed dose combinations in the Indian drug market: An evaluation of prescribing pattern using WHO guidelines. Int J Basic Clin Pharmacol 2013;2:52-457.
6. Report of DTAB Subcommittee Appointed on 19/02/18 to Examine the Matters Related to 344 Plus 5 FDCs in Compliance with the Hon. Supreme Court Order Delhi, DGHS. 701p. Available from: https:// www.cdsco.gov.in.
7. Guidelines for Registration of Fixed-dose Combination Medicinal Products. Report Number 929. Geneva: World Health Organization; 2005.
8. Drugs and Cosmetics Act of 1940 (as Amended up to 30th June, 2005), Appendix VI. Available from: http://www.cdsco.nic.in/html/ Drugs&CosmeticAct.pdf.
9. Singh GN. To: All State/UT Drug Controllers. Subject: Approval of the safety and efficacy of Fixed Dose Combinations (FDCs) Permitted for Manufacture for Sale in the Country Without Due Approval from the Office of DCG (I)-regarding. F. No. 4-01/2013-DC (Misc13- PSC); 2013. Available from: http://www.cdsco.nic.in/writereaddata/ Approval_of_the_safety_and%20effi cacy_FDC.pdf. [Last accessed on 2019 Sep 16].
10. Chaudhury RR. Report of the Prof. Rajnit Roy Chaudhury Expert Committee to Formulate Policy and Guidelines for Approval of New Drugs, Clinical Trials and Banning of Drugs; 2013. Available from: http://www.cdsco.nic.in/writereaddata/Report_of_Dr_Ranjit_Roy.pdf. [Last accessed on 2019 Sep 16].
11. Policy Guidelines for Approval of Fixed Dose Combinations (FDCs) in India. CDSCO, Directorate General of Health Services, Ministry of Health and Family Welfare; 2013. Available from: http://www.cdsco. nic.in/writereaddata/Report%20of%20Dr.C.K%20Kokate. pdf. [Last accessed on 2019 Sep 16].
12. Minutes of the 79th Meeting of Drugs Technical Advisory Board held on 16th May 2018 at DGHS, Nirman Bhawan, New Delhi; 2018. Available from: http://www.cdsco.nic.in/writereaddata/Final%20 Minutes%20for%2079th%20DTAB%20meeting%20held%20on%20 16_05_2018(1).pdf. [Last accessed on 2019 Sep 16]
13. Complete List of 344 Drugs Banned by the Ministry of Health and Family Welfare. 2018. Available from: https://www.nhp.gov.in/ Complete-list-of-344-drugs-banned-by-the-Ministry-of-Health- Family-welfare_pg. [Last accessed on 2019 Apr 17].
14. Hussein SH. Cough Mixtures; 1996. Available from: http://www.prn2. usm.my/mainsite/bulletin/sun/1996/ sun39.html.
15. Hecht A. The Common Cold: Relief But no Cure. 1976. Available from: http://www.hoptechno.com/book64.htm. [Last accessed on 2019 Sep 17].
16. Sreedhar D, Janodia MD. Fixed dose combinations: Rational or Irrational? Cur Sci 2008;95:581-3
17. Shah S, Patel J, Desai M, Dikshit RK. Critical analysis of antimicrobial and respiratory fixed dose combinations available in Indian market. Int J Med Public Health 2015;5:161-4.
18. Schroeder K, Fahey T. Over the counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2004;18:CD001831.
19. West S, Brandon B, Stolley P, Rumrill R. A review of antihistamines and the common cold. Pediatrics 1975;56:100-7.
20. FDA Recommends Ban on Cough and Cold Medicines for Children; 2008. Available from: http://www.caritasstelizabeths.org/Newsletters. asp?PageId=P09097. [Last accessed on 2019 Sep 28].
21. Minutes of the 60th Meeting of Drugs Technical Advisory Board Held. Bhavan: In the Committee Room, FDA; 2011. p. 18.
22. Berry H, Hutchinson DR Tizanidine and ibuprofen in acute low-back pain: Results of a double-blind multicentre study in general practice. J Int Med Res 1988;16:83-91.
23. Sackier JM. Adverse reaction to antihistamine-decongestant. Allergy Asthma Immunol 1995;74:356.
24. Satoskar RS. Pharmacology and Pharmacotherapeutics. 25th ed., Ch. 26. Netherlands: Elsevier; 2017. p. 363-9.
25. Tandon VR, Chandail V, Khajuria V, Gillani Z. Gastrointestinal bleed induced by a fixed dose combination of rabeprazole and diclofenac sodium. Indian J Pharmacol 2014;46:555-6.
Statistics
43 Views | 72 Downloads
Citations
How to Cite
PATEL, S., S. SHAH, and C. DESAI. “AN ANALYSIS OF BANNED FIXED-DOSE COMBINATIONS IN INDIA”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 2, Feb. 2021, pp. 158-61, doi:10.22159/ajpcr.2021.v14i2.40368.
Section
Original Article(s)